- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Lyell Immunopharma: Citizens bestätigt "Market Outperform" nach Fortschritten in Studien | 1 | Investing.com Deutsch | ||
| Mo | Citizens reiterates Lyell Immunopharma stock rating on trial progress | 1 | Investing.com | ||
| 12.03. | Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Lyell Immunopharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 09.03. | Lyell Immunopharma closes $50M equity tranche, names new CFO | 1 | Investing.com | ||
| 09.03. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer | 1 | GlobeNewswire (USA) | ||
| 09.03. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Citizens initiates Lyell Immunopharma stock at outperform, $34 target | 1 | Investing.com | ||
| 12.02. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | 1.014 | GlobeNewswire (Europe) | PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell... ► Artikel lesen | |
| 22.12.25 | Lyell Immunopharma pops on recent ASH data, immunotherapy expansion | 4 | Seeking Alpha | ||
| 07.12.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 05.12.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Lyell Immunopharma reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Lyell Immunopharma buys exclusive global rights to colorectal cancer drug | 1 | Seeking Alpha | ||
| 10.11.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | 165 | GlobeNewswire (Europe) | LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal... ► Artikel lesen | |
| 10.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Lyell Immunopharma: Vielversprechende Daten zu dualer CAR-T-Zelltherapie bei Lymphomen | 1 | Investing.com Deutsch | ||
| 03.11.25 | Lyell Immunopharma, Inc: Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 03.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,030 | -15,73 % | Medigene: Zurückziehung - 18.11.2025 | ||
| AMGEN | 298,60 | -0,85 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| BIOGEN | 157,75 | -0,25 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| GALAPAGOS NV | 27,720 | -1,21 % | Galapagos NV: Galapagos Receives Transparency Notification from Bank of America | Mechelen, Belgium; March 117, 2026, 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.
Pursuant to Belgian... ► Artikel lesen | |
| IMMATICS | 8,270 | +1,10 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,200 | -0,83 % | Cellares Corp: Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform | Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,405 | +0,44 % | Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings | ||
| TSCAN THERAPEUTICS | 1,030 | -1,44 % | TScan Therapeutics, Inc.: TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 | Completed enrollment of Cohort C in the Phase 1 ALLOHA trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting... ► Artikel lesen | |
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,83 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -4,72 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen |
LYELL IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -7,95 % bei einem Aktienkurs von 19,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.